Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, Vangeneugden T, Miralles D, Meyer SD, Parys W, Lefebvre E; TMC114-C208 Study Group; TMC114-C215 Study Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):24-31.

PMID:
17621237
2.

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W, Vangeneugden T; POWER 1 study group.

AIDS. 2007 Feb 19;21(4):395-402.

PMID:
17301557
3.

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):179-82. doi: 10.1097/QAI.0b013e318183a959.

PMID:
18769351
4.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups.

Lancet. 2007 Apr 7;369(9568):1169-78. Erratum in: Lancet. 2008 Jan 12;371(9607):116.

PMID:
17416261
5.

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.

AIDS. 2008 Jul 31;22(12):1389-97. doi: 10.1097/QAD.0b013e32830285fb.

PMID:
18614861
6.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.

HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.

7.

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, Workman C, Van De Casteele T, De Doncker P, Lathouwers E, Tomaka F.

AIDS. 2011 Apr 24;25(7):929-39. doi: 10.1097/QAD.0b013e328345ee95.

PMID:
21346512
8.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

PMID:
19487905
9.

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, van Baelen B, Lefebvre E; POWER 2 Study Group.

AIDS. 2007 Mar 30;21(6):F11-8.

PMID:
17413685
10.

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA; ESS40011 (STARR) Study Team.

BMC Infect Dis. 2003 Jun 10;3:10.

11.

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F.

HIV Med. 2013 Aug;14(7):437-44. doi: 10.1111/hiv.12024. Epub 2013 Mar 10.

12.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
13.

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F.

Antivir Ther. 2009;14(6):859-64. doi: 10.3851/IMP1301.

PMID:
19812449
14.

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

Bánhegyi D, Katlama C, da Cunha CA, Schneider S, Rachlis A, Workman C, De Meyer S, Vandevoorde A, Van De Casteele T, Tomaka F.

Curr HIV Res. 2012 Mar;10(2):171-81.

PMID:
22339125
15.

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C; RADAR Study Group.

J Med Virol. 2013 Jan;85(1):8-15. doi: 10.1002/jmv.23404. Epub 2012 Sep 28.

PMID:
23024008
16.

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Boffito M, Miralles D, Hill A.

HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. Review. Erratum in: HIV Clin Trials. 2009 Mar-Apr;10(2):vi. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
19203907
17.

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.

Arastéh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E; TMC114-C207 Study Team.

AIDS. 2005 Jun 10;19(9):943-7.

PMID:
15905675
18.

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S.

AIDS. 2009 Sep 24;23(15):2005-13. doi: 10.1097/QAD.0b013e328330abaa.

PMID:
19724191
19.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.

AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec.

PMID:
19474650
20.

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.

Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719.

PMID:
21311113

Supplemental Content

Support Center